E. Schleifman

发表

P. Glazer, J. Chin, E. Schleifman, 2008, Methods in molecular biology.

Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.

T. Mok, S. Peters, F. de Marinis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correction: Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PLoS ONE.

Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PloS one.

Polymer delivery systems for site-specific genome editing.

P. Glazer, W. Saltzman, E. Schleifman, 2011, Journal of controlled release : official journal of the Controlled Release Society.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, M. Socinski, V. Velcheti, 2022, Nature Medicine.

Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice

P. Glazer, W. Saltzman, D. Greiner, 2013, Molecular therapy. Nucleic acids.

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

P. Hegde, T. Mok, D. Gandara, 2017, Pneumologie.

Peptide nucleic acid-mediated recombination for targeted genomic repair and modification.

P. Glazer, E. Schleifman, 2014, Methods in molecular biology.

Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo

P. Glazer, W. Saltzman, K. Anandalingam, 2012, Gene Therapy.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.

G. Hampton, P. Hegde, W. Forrest, 2014, The oncologist.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.

Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

R. Bourgon, P. Hegde, T. Powles, 2018 .

Repair and recombination induced by triple helix DNA.

P. Glazer, Peter M Glazer, Joanna Y Chin, 2007, Frontiers in bioscience : a journal and virtual library.

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Doron Lipson, Bernard Fendler, Jeffrey P. Gregg, 2018, The Journal of molecular diagnostics : JMD.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

G. Hampton, J. Fridlyand, T. Wilson, 2016, npj Breast Cancer.

102PAnalytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)

D. Lipson, C. Cummings, C. Malboeuf, 2017 .

Interactions among Ytm1, Erb1, and Nop7 required for assembly of the Nop7-subcomplex in yeast preribosomes.

J. Woolford, J. Jakovljevic, E. Schleifman, 2008, Molecular biology of the cell.

Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors.

P. Glazer, W. Saltzman, E. Schleifman, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers

G. Hampton, L. Molinero, L. Amler, 2016, PLoS ONE.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

G. Hampton, J. Fridlyand, T. Wilson, 2014, Breast Cancer Research and Treatment.

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

T. Mok, D. Gandara, S. Novello, 2021, Annals of Oncology.

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

M. Socinski, V. Velcheti, D. Shames, 2019, Annals of Oncology.

1383TiPBlood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

Edward S. Kim, M. Socinski, T. Mok, 2017 .

Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors

T. Clark, D. Lipson, V. Miller, 2016 .

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).

M. Socinski, V. Velcheti, D. Fabrizio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab

D. Lipson, C. Cummings, C. Malboeuf, 2018, Immunology.

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

G. Hampton, T. Wilson, J. Spoerke, 2014, PloS one.

Abstract 3965: Rigorous validation of a clinical circulating tumor DNA assay for cancer molecular profiling

T. Clark, D. Lipson, G. Otto, 2016 .

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.

P. Glazer, P. Uchil, O. Kutsch, 2011, Chemistry & biology.

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay

P. Hegde, Hsin-Ta Wu, T. Powles, 2023, Frontiers in oncology.

Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors.

T. Clark, D. Lipson, V. Miller, 2016 .

Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

T. Mok, R. Dziadziuszko, D. Shames, 2019, Annals of Oncology.